To evaluate the therapeutic efficacy and safety of JAK inhibitor abrocitinib in patients with localized granuloma annulare (GA) and to review the available cases documented in English. We presented a patient who had a persistent, localized granuloma anulare (GA) for one year and did not respond to traditional therapies. This patient was treated with oral abrocitinib at a dosage of 150 mg daily. After 6 weeks of treatment with abrocitinib, the patient exhibited notable symptom improvement with no new lesions. No adverse events or recurrences were reported during the 5-month follow-up period. Abrocitinib may be a promising and safe treatment option for patients with localized GA who do not respond to traditional therapies.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1080/09546634.2024.2313090 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
English version of clinical practice guidelines for the management of atopic dermatitis 2024.
J Dermatol
December 2024
Medical Informatics and Management, Institute of Medicine, University of Tsukuba, Tsukuba, Japan.
Article Synopsis
- The 2024 clinical practice guidelines for atopic dermatitis (AD) focus on effectively managing this condition characterized by itchy, relapsing eczema.
- The primary goal of treatment is to quickly induce remission by reducing skin inflammation and itching, primarily using topical anti-inflammatory medications.
- The updated guidelines introduce five new treatments and emphasize the importance of evaluating research and weighing the pros and cons of various medical options to enhance patient outcomes.
Successful treatment of SAPHO syndrome with oral abrocitinib: a case report.
J Dermatolog Treat
December 2024
Department of Dermatology, The Second Hospital of Dalian Medical University, Dalian, China.
Aim: SAPHO (synovitis, acne, pustulosis, hyperostosis and osteitis) syndrome is a rare autoimmune disorder characterized by typical cutaneous lesions (palmoplantar pustulosis and eruptive acne) and osteoarticular symptoms (aseptic osteomyelitis and joint inflammation). This study aims to evaluate the therapeutic efficacy and safety of Janus kinase 1 (JAK1) inhibitor abrocitinib in patients with SAPHO syndrome.
Methods: We presented a patient with SAPHO syndrome with accelerated disease progression who did not respond to traditional therapies.
Concurrent Refractory Atopic Dermatitis and Generalized Vitiligo Successfully Treated with Abrocitinib: A Case Report.
J Asthma Allergy
December 2024
Department of Dermatology, The First Affiliated Hospital of Chongqing Medical University, Chongqing, 400010, People's Republic of China.
Atopic dermatitis (AD) may sometimes be comorbid with vitiligo. However, these therapeutic agents are often slow acting and lead to various adverse effects, resulting in poor patient compliance. This report describes a 65-year-old male patient with refractory moderate-to-severe atopic dermatitis (AD) and generalized vitiligo.
View Article and Find Full Text PDFAbrocitinib: A Comprehensive Review of its Efficacy and Safety in Dermatology.
Indian Dermatol Online J
October 2024
Department of Immunopathology, Postgraduate Institute of Medical Education and Research, Chandigarh, India.
Article Synopsis
- Abrocitinib is a new oral medication that specifically inhibits JAK-1, targeting inflammation pathways.
- It is currently approved for moderate-to-severe atopic dermatitis and shows potential for treating other inflammatory skin conditions.
- Clinical trials have confirmed its effectiveness and safety, but its future use will depend on practicality within the Indian healthcare context.
Type 2 cytokine-JAK1 signaling is involved in the development of dry skin-induced mechanical alloknesis.
J Dermatol Sci
October 2024
Juntendo Itch Research Center (JIRC), Institute for Environmental and Gender-Specific Medicine, Juntendo University Graduate School of Medicine, Urayasu, Japan; Department of Dermatology, Juntendo University Urayasu Hospital, Urayasu, Japan. Electronic address:
Background: Mechanical alloknesis (m-alloknesis) is itch hypersensitivity induced by normally innocuous stimuli. It is sometimes observed in dry skin based itch-related diseases such as atopic dermatitis (AD), and often triggers the vicious itch-scratch cycle. The acetone-ether and water (AEW) mouse model mimics dry skin-induced m-alloknesis, yet its underlying mechanism remains unclear.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!